Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Dow
Baxter
Medtronic
McKesson

Last Updated: January 29, 2022

DrugPatentWatch Database Preview

Claims for Patent: 10,456,399


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,456,399
Title:Method for treating cancer patients with severe renal impairment
Abstract: A method for treating cancer in patients with creatinine clearance of 15 mL/min or more and less than 30 mL/min, including dividing a combination drug containing .alpha.,.alpha.,.alpha.-trifluorothymidine (FTD) and 5-chloro-6-[(2-iminopyrrolidine-1-yl)methyl]pyrimidine-2,4(1H,3H)-dione hydrochloride in a molar ratio of 1:0.5, in a dose of 30 to 50 mg/m.sup.2/day as FTD-equivalent, into two to four times a day, and orally administering it to the patient.
Inventor(s): Yoshida; Kenichiro (Tsukuba, JP)
Assignee: TAIHO PHARMACEUTICAL CO., LTD. (Chiyoda-ku, JP)
Application Number:16/054,073
Patent Claims: 1. A method for treating cancer which is one of gastrointestinal cancer, large bowel cancer and breast cancer, comprising: detecting a creatinine clearance of a patient; and orally administering to the patient with a creatinine clearance of less than 30 mL/min a combination drug comprising .alpha.,.alpha.,.alpha.-trifluorothymidine (FTD) and 5-chloro-6-[(2-iminopyrrolidine-1-yl)methyl]pyrimidine-2,4(1H,3H)-dione hydrochloride in a molar ratio of 1:0.5, a daily dose of 30 to 40 mg/m.sup.2/day as FTD-equivalent, divided into two to four portions for administration.

2. The method for treating cancer according to claim 1, wherein the combination drug is administered to the patient with a creatinine clearance of 15 mL/min or more and 29 mL/min or less.

3. The method for treating cancer according to claim 1, wherein a dose of 40 mg/m.sup.2/day as FTD-equivalent is divided in two portions.

4. The method for treating cancer according to claim 1, wherein an administration schedule is 5-day consecutive oral administrations and 2-day rest, per week.

5. The method for treating cancer according to claim 1, wherein an administration schedule of 5-day consecutive oral administrations and 2-day rest is repeated twice, followed by rest for 14 days.

6. The method for treating cancer according to claim 1, wherein the cancer is gastrointestinal cancer or breast cancer.

7. The method for treating cancer according to claim 1, wherein the cancer is large bowel cancer.

8. The method for treating cancer according to claim 1, wherein the cancer is gastrointestinal cancer.

9. The method for treating cancer according to claim 1, wherein the cancer is breast cancer.

10. The method for treating cancer according to claim 2, wherein a dose of 40 mg/m.sup.2/day as FTD-equivalent is divided in two portions.

11. The method for treating cancer according to claim 2, wherein an administration schedule is 5-day consecutive oral administrations and 2-day rest, per week.

12. The method for treating cancer according to claim 2, wherein an administration schedule of 5-day consecutive oral administrations and 2-day rest is repeated twice, followed by rest for 14 days.

13. The method for treating cancer according to claim 2, wherein the cancer is gastrointestinal cancer or breast cancer.

14. The method for treating cancer according to claim 2, wherein the cancer is large bowel cancer.

15. The method for treating cancer according to claim 2, wherein the cancer is gastrointestinal cancer.

16. The method for treating cancer according to claim 2, wherein the cancer is breast cancer.

17. The method for treating cancer according to claim 3, wherein an administration schedule is 5-day consecutive oral administrations and 2-day rest, per week.

18. The method for treating cancer according to claim 3, wherein an administration schedule of 5-day consecutive oral administrations and 2-day rest is repeated twice, followed by rest for 14 days.

19. The method for treating cancer according to claim 3, wherein the cancer is gastrointestinal cancer or breast cancer.

20. The method for treating cancer according to claim 3, wherein the cancer is large bowel cancer.

21. The method for treating cancer according to claim 3, wherein the cancer is gastrointestinal cancer.

22. The method for treating cancer according to claim 3, wherein the cancer is breast cancer.

23. The method for treating cancer according to claim 4, wherein the cancer is gastrointestinal cancer or breast cancer.

24. The method for treating cancer according to claim 4, wherein the cancer is large bowel cancer.

25. The method for treating cancer according to claim 4, wherein the cancer is gastrointestinal cancer.

26. The method for treating cancer according to claim 4, wherein the cancer is breast cancer.

27. The method for treating cancer according to claim 5, wherein the cancer is gastrointestinal cancer or breast cancer.

28. The method for treating cancer according to claim 5, wherein the cancer is large bowel cancer.

29. The method for treating cancer according to claim 5, wherein the cancer is gastrointestinal cancer.

30. The method for treating cancer according to claim 5, wherein the cancer is breast cancer.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
McKinsey
Colorcon
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.